Johnson and Johnson Vaccine found 66% effective
The vaccine, developed at J&J’s Janssen Pharmaceutical Companies, will be the first single-dose vaccine introduced for commercial use, once cleared for emergency use. Johnson & Johnson said its single-dose vaccine was 72% effective in preventing COVID-19 in the United States but a lower rate of 66% was observed globally in the large trial conducted across three continents and against multiple variants.
If cleared, J&J’s vaccine could go a long way toward ending the pandemic. Competing vaccines from Moderna Inc. and Pfizer Inc. have generated stronger overall efficacy rates of more than 90%, but require two shots to be given before their full benefits take hold. J&J’s shot also can be kept in a refrigerator for three months, while those from Pfizer and Moderna must be kept frozen.
This J&J announcement comes after AstraZeneca had announced it would only be able to deliver a fraction of the vaccine doses agreed upon for the first quarter. It claimed there were production problems at its European plants.